Chemical process innovationstartup NuSynth Technologies has raised Rs 36.5 crore (around $4 million) in a seed funding round co-led by Avaana Capital and Shastra VC, as it seeks to develop more cost-efficient and sustainable methods for manufacturing complex chemicals.
/indianstartupnews/media/media_files/2026/06/17/desktop-728-x-90-1-2026-06-17-17-20-35.png)
The round also included participation from seven to eight angel investors.
NuSynth is developing a research and development (R&D) platform that uses AI and experimental data to identify alternative chemical synthesis routes. The startup aims to lower manufacturing costs, improve production yields, shorten development cycles and reduce dependence on imported raw materials, particularly from China.
The fresh capital will be used to expand its R&D capabilities, recruit scientists, develop proprietary chemical processes and strengthen its AI technology.
How NuSynth plans to improve chemical manufacturing
India has established substantial chemical manufacturing capacity but continues to depend on overseas suppliers for several advanced chemical intermediates, including those used in pharmaceutical production.
These intermediates are essential building blocks in the manufacture of active pharmaceutical ingredients (APIs) and other speciality chemicals.
NuSynth aims to address some of these challenges by redesigning chemical manufacturing processes rather than making incremental improvements to existing methods.
Its platform evaluates raw materials, chemical reaction pathways and process economics to identify alternative synthesis routes that could improve efficiency, safety, sustainability and scalability.
The startup uses predictive synthesis models and an AI engine that analyses experimental data to guide subsequent research. By drawing on the results of previous experiments, including unsuccessful ones, the platform is designed to help researchers identify promising approaches and reduce the time required for chemical process development.
“We are talking about R&D as a growth engine,” co-founder Poorvank Purohit, who previously served as managing director and CEO of Solara Active Pharma Sciences said.
Initial focus on pharmaceutical and electronics chemicals
NuSynth is initially focusing on pharmaceuticaland electronics chemicals, with plans to expand into nutraceuticals, flavours and fragrances, as well as other industries that rely on complex chemical processes.
The startup is currently working on four to five molecules and has developed proprietary reaction technologies that it believes could be applied across multiple chemical products and industries.
It is also in discussions with potential customers and expects to begin commercialising its proprietary processes in the second half of 2027, following customer sampling and validation batches.
To support the transition from laboratory research to industrial production, NuSynth has established a network of more than 20 manufacturing partners across India, which could help scale up production when required.
How the funding will be used
NuSynth plans to use the fundingto strengthen its research infrastructure, build an initial portfolio of proprietary chemical processes and expand its scientific and technical teams. It operates an R&D laboratory and a pilot plant in Mysuru and is developing another research facility in Bengaluru.
Its longer-term strategy is to develop chemical manufacturing processes that can be adapted for commercial applications across different sectors, rather than limiting its research to individual products.
NuSynth’s founding team includes Poorvank Purohit, Dr Ramesha A R, Abhishek Deo and Dipak Bajaj. The team brings together expertise in chemical research, commercial operations and business development.
According to the founders, the company expects to seek additional funding as it approaches commercialisation in 2027.
